Newly Funded Research Grants 2022
Dr. Edwin Jabbari, Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK - New Pipeline Grant
Fluid markers of LRRK2 as a determinant of PSP risk and disease progression
Dr. Shu Chen, Pathology, University of Alabama, Birmingham, AL - New Pipeline Grant
Development of RT-QuIC Assays of Skin Biopsy for Early Diagnosis of PSP
Dr. Johannes Levin, Department of Neurology, LMU Hospital, Munich, Germany - New Pathway Grant
In vivo assessment of reactive astrogliosis in PSP
Dr. Naomi Visanji, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada - New Pathway Grant
Prioritizing the in vivo modeling of Progressive Supranuclear Palsy
Dr. Sarah Hopp, Glenn Biggs Institute for Neurodegenerative Disorders, The University of Texas Health Science Center, San Antonio, TX
Harnessing Microglia to Internalize and Degrade Tau
Dr. Mikael Simons, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Evaluation of Fluid-Based and Imaging Biomarkers for Interventional Trials in PSP
Dr. Hong Xu, Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
Understanding the Diversity of Tau Pathogenesis in PSP
Ongoing Funded Grants
Dr. Marta Olah, Department of Neurology, Columbia University, New York, NY
Identification of Microglia Phenotypes Associated with Tau Pathology in PSP and CBD
Dr. Maria Catarina Lima da Silva, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Investigation of ULK1-Based Autophagy Activators as Therapeutics for Tauopathies
Dr. Daniel H. Geschwind, Department of Neurology, UCLA, Los Angeles, CA
Aminopeptidase Enhancers as Novel PSP Pharmacotherapies
Dr. Rachel Baily, Center for Alzheimer's and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX
Gene Replacement Therapy for Tauopathies
Dr. Franziska Hopfner, Department of Neurology, Hannover Medical School, Hannover, Germany
MicroRNA profile of isolated brain cell populations in PSP
Dr. Chao Peng, Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, California
The Role of Post-Translational Modifications on Tau Transmission in PSP
Dr. Rohan de Silva, UCL Queen Square Institute of Neurology, London, UK
Do distinct 4R-tau seeding strains cause disease heterogeneity in PSP and CBD?
Dr. Rik van der Kant, Functional Genomics Department, Vrije Universiteit Amsterdam, Amsterdam, Holland
Low-dose efavirenz as a disease-modifying intervention for primary Tauopathies
Dr. Rueben Das, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
Connecting GWAS signal in TAU Locus to Effector Variant in Tauopathies
Dr. Amanda L. Woerman, University of Massachusetts, Amherst, MA
Investigating PSP and CBD Tau Strain Biology to Support Novel Diagnostic Development
Dr. John M. Ringman, Keck School of Medicine at the University of Southern California, Los Angeles, CA
Genotyping Familial Progressive Supranuclear Palsy
Dr. David C. Butler, Neural Stem Cell Institute, Regenerative Research Foundation, Rensselaer, NY
Bifunctional Intrabodies to Lower Tau
Dr. Gal Bitan, University of California, Los Angeles
Biomarkers In Brain-Derived Blood Exosomes For Improved PSP Diagnosis
Dr. Maria-Elena Avale, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Buenos Aires, Argentina
Dissecting Neuronal Dysfunctions Under 3R:4R Tau Isoforms Imbalance